Ann Lee

At BMS, Dr. Lee leads teams responsible for developing new cell therapy processes and technologies, manufacturing cell therapy products, designing new facilities, and building the global supply chain to deliver these new medicines for patients. Previously, she served as Executive Vice President of Technical Operations at Juno Therapeutics, which was acquired by BMS via Celgene. Prior to Juno, Dr. Lee joined Genentech in 2005, and she became SVP, Genentech and Head of Global Technical Development at Roche in 2009. She was responsible for developing and delivering all clinical stage products in Roche’s global pipeline, as well as technology transfers and technical support for all commercial products. Earlier, she was at Merck & Co., where she led and developed new vaccines and technologies in R&D, and then was responsible as VP for process engineering and technical operations at 10 chemical sites around the world. Over the course of her career, she has contributed to the development of hundreds of new investigational drugs, and the licensure and commercialization of 25 new vaccines and medicines, with the most recent being two new CAR-T cell products for blood cancers.

Dr. Lee has authored over 40 scientific publications and holds several patents. She is a member of the National Academy of Engineering, fellow of American Academy of Arts and Sciences, American Institute of Medical and Biological Engineering, and member of the Washington State Academy of Sciences. She serves on the Board of Directors for American Institute of Chemical Engineers, the Alliance of Regenerative Medicine, and JW Therapeutics. She earned her undergraduate degree from Cornell University and a masters and Ph.D. in Biochemical Engineering with a concentration in molecular biophysics and biochemistry from Yale University.